Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X.
J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29.
Donor-Recipient Chimeric Cell Transplantation as the Bridging Therapy for Mitigating Total Body Irradiation-Induced Injury.
Siemionow M, Bieda K, Stawarz K, Cyran M, Chambily L, Kusza K.
Stem Cells Dev. 2024 Jul;33(13-14):343-354. doi: 10.1089/scd.2024.0068. Epub 2024 May 23.
Transplantation of Donor-Recipient Chimeric Cells Restores Peripheral Blood Cell Populations and Increases Survival after Total Body Irradiation-Induced Injury in a Rat Experimental Model.
Siemionow M, Cyran M, Stawarz K, Chambily L, Kusza K.
Arch Immunol Ther Exp (Warsz). 2024 May 23;72(1). doi: 10.2478/aite-2024-0009. eCollection 2024 Jan 1.
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X, Shuai Y, Han Y, Zhang N, Liu Y, Yao H, Wang X, He G, Chen D, Fan F, Chang AH, Su Y, Yi H.
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells.
Verdonck LF, van Blokland WT, Bosboom-Kalsbeek EK, van Heugten HG, Tilanus MG, de Weger RA.
Bone Marrow Transplant. 1996 Aug;18(2):389-95.
Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
Jiang Y, Feng D, Zhu J, Wei D, Zhao C, Liu H, Shao S, Wang C.
Front Immunol. 2024 Apr 30;15:1381308. doi: 10.3389/fimmu.2024.1381308. eCollection 2024.
Stem cell engraftment strategies.
Quesenberry PJ, Stewart FM, Becker P, D'Hondt L, Frimberger A, Lambert JF, Colvin GA, Miller C, Heyes C, Abedi M, Dooner M, Carlson J, Reilly J, McAuliffe C, Stencel K, Ballen K, Emmons R, Doyle P, Zhong S, Wang H, Habibian H.
Ann N Y Acad Sci. 2001 Jun;938:54-61; discussion 61-2. doi: 10.1111/j.1749-6632.2001.tb03574.x.
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG, Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS.
Br J Haematol. 2012 Feb;156(4):516-22. doi: 10.1111/j.1365-2141.2011.08944.x. Epub 2011 Dec 15.
Donor T-cell and myeloid chimerism is higher after cord blood transplant than with other cell sources.
Nadaf R, Lee H, Mustafa O, Bonney D, Mirci-Danicar O, Hanasoge-Nataraj R, Senthil S, Horgan C, Logan A, Poulton K, Wynn R.
Cytotherapy. 2025 Nov;27(11):1338-1343. doi: 10.1016/j.jcyt.2025.07.003. Epub 2025 Jul 18.
Donor- and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantation.
Sun T, Ma JF, Jia X, Xu SZ, Liu SH, Lyu XY, Huang SM, Wu YJ, Yao Z, Qian CS, Li Z, Yu L, Dai HP, Gong WJ, Xue SL.
Cytotherapy. 2026 Jun;28(6):102118. doi: 10.1016/j.jcyt.2026.102118. Epub 2026 Feb 16.
